Compare Stocks: MAZE, SRRK, ORKA, and MIRM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MAZE Maze Therapeutics	$25.99 -1.7%	$26.90	$21.95 ▼ $53.65	$1.44B	2.16	663,270 shs	285,916 shs
MIRM Mirum Pharmaceuticals	$82.17 +3.7%	$96.63	$63.23 ▼ $130.00	$5.34B	0.61	851,446 shs	527,500 shs
ORKA Oruka Therapeutics	$79.80 -0.5%	$95.45	$20.25 ▼ $115.51	$5.28B	-0.37	1.09 million shs	472,835 shs
SRRK Scholar Rock	$42.80 +0.8%	$52.01	$27.07 ▼ $61.76	$5.22B	0.61	1.43 million shs	792,208 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MAZE Maze Therapeutics	0.00%	-2.18%	+0.84%	-17.38%	-3.96%
MIRM Mirum Pharmaceuticals	-2.68%	-9.47%	-21.46%	-38.36%	+9.27%
ORKA Oruka Therapeutics	-4.98%	-2.40%	-13.33%	-5.00%	+294.39%
SRRK Scholar Rock	-2.19%	-11.10%	-23.28%	-24.24%	+6.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MAZE Maze Therapeutics	$25.99 -1.7%	$26.90	$21.95 ▼ $53.65	$1.44B	2.16	663,270 shs	285,916 shs
MIRM Mirum Pharmaceuticals	$82.17 +3.7%	$96.63	$63.23 ▼ $130.00	$5.34B	0.61	851,446 shs	527,500 shs
ORKA Oruka Therapeutics	$79.80 -0.5%	$95.45	$20.25 ▼ $115.51	$5.28B	-0.37	1.09 million shs	472,835 shs
SRRK Scholar Rock	$42.80 +0.8%	$52.01	$27.07 ▼ $61.76	$5.22B	0.61	1.43 million shs	792,208 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MAZE Maze Therapeutics	0.00%	-2.18%	+0.84%	-17.38%	-3.96%
MIRM Mirum Pharmaceuticals	-2.68%	-9.47%	-21.46%	-38.36%	+9.27%
ORKA Oruka Therapeutics	-4.98%	-2.40%	-13.33%	-5.00%	+294.39%
SRRK Scholar Rock	-2.19%	-11.10%	-23.28%	-24.24%	+6.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MAZE Maze Therapeutics	3.08	Buy	$63.40	143.99% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$142.56	73.50% Upside
ORKA Oruka Therapeutics	2.82	Moderate Buy	$128.91	61.55% Upside
SRRK Scholar Rock	2.94	Moderate Buy	$66.75	55.96% Upside

Current Analyst Ratings Breakdown

Latest MAZE, SRRK, ORKA, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/7/2026	ORKA Oruka Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/29/2026	MIRM Mirum Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$123.00 ➝ $130.00
9/28/2026	MIRM Mirum Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$144.00
9/28/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$145.00 ➝ $160.00
9/28/2026	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$140.00 ➝ $195.00
9/24/2026	SRRK Scholar Rock	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$76.00 ➝ $77.00
9/24/2026	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$120.00
9/24/2026	MAZE Maze Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
9/24/2026	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$165.00
9/24/2026	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
9/23/2026	MAZE Maze Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$50.00

(Data available from 10/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MAZE Maze Therapeutics	$167.50M	8.62	N/A	N/A	$7.38 per share	3.52
MIRM Mirum Pharmaceuticals	$521.31M	10.23	$0.05 per share	1,597.32	$6.12 per share	13.43
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$9.69 per share	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	$2.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MAZE Maze Therapeutics	-$131.12M	-$2.52	N/A	N/A	N/A	N/A	-34.94%	-30.18%	N/A
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)
ORKA Oruka Therapeutics	-$105.43M	-$2.03	N/A	N/A	N/A	N/A	-21.65%	-20.88%	11/11/2026 (Estimated)
SRRK Scholar Rock	-$377.94M	-$3.45	N/A	N/A	N/A	N/A	-160.19%	-87.18%	11/13/2026 (Estimated)

Latest MAZE, SRRK, ORKA, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	MIRM Mirum Pharmaceuticals	-$0.53	N/A	N/A	N/A	$178.06 million	N/A
8/11/2026	Q2 2026	MAZE Maze Therapeutics	-$0.76	-$0.76	N/A	-$0.76	N/A	N/A
8/10/2026	Q2 2026	ORKA Oruka Therapeutics	-$0.5125	-$0.55	-$0.0375	-$0.55	N/A	N/A
8/6/2026	Q2 2026	SRRK Scholar Rock	-$0.8405	-$0.84	+$0.0005	-$0.84	$3.33 million	N/A
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MAZE Maze Therapeutics	0.09	18.31	18.31
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74
ORKA Oruka Therapeutics	N/A	38.51	38.51
SRRK Scholar Rock	0.77	7.02	7.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MAZE Maze Therapeutics	N/A
MIRM Mirum Pharmaceuticals	N/A
ORKA Oruka Therapeutics	56.44%
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
MAZE Maze Therapeutics	5.30%
MIRM Mirum Pharmaceuticals	8.32%
ORKA Oruka Therapeutics	23.49%
SRRK Scholar Rock	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MAZE Maze Therapeutics	141	55.55 million	52.61 million	N/A
MIRM Mirum Pharmaceuticals	433	64.93 million	59.53 million	Optionable
ORKA Oruka Therapeutics	68	66.21 million	50.66 million	N/A
SRRK Scholar Rock	289	121.79 million	109.24 million	Optionable

MAZE, SRRK, ORKA, and MIRM Headlines

Recent News About These Companies

Scholar Rock (NASDAQ:SRRK) Stock Price Up 2.8% - Should You Buy?

1 hour ago | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Shares Down 5.1% - Here's Why

October 5 at 1:59 PM | marketbeat.com

Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

September 30, 2026 | prnewswire.com

FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals

September 28, 2026 | finance.yahoo.com

Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says

September 25, 2026 | finance.yahoo.com

How Scholar Rock Holding Corporation (SRRK) Affects Rotational Strategy Timing

September 23, 2026 | news.stocktradersdaily.comN

Scholar Rock (NASDAQ:SRRK) Shares Up 6% Following Analyst Upgrade

September 22, 2026 | marketbeat.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 21, 2026

September 22, 2026 | biospace.comB

Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

September 21, 2026 | marketbeat.com

Bank of America Corp DE Takes $53.47 Million Position in Scholar Rock Holding Corporation $SRRK

September 21, 2026 | marketbeat.com

Scholar Rock Holding (SRRK) Receives a Buy from Piper Sandler

September 17, 2026 | theglobeandmail.com

Scholar Rock (NASDAQ:SRRK) Raised to Strong-Buy at Jefferies Financial Group

September 17, 2026 | marketbeat.com

HC Wainwright Lowers Earnings Estimates for Scholar Rock

September 17, 2026 | marketbeat.com

Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?

September 16, 2026 | insidermonkey.com

Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions

September 15, 2026 | finance.yahoo.com

Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says

September 15, 2026 | finance.yahoo.com

Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play

September 15, 2026 | seekingalpha.com

Scholar Rock downgraded at Barclays despite FDA approval of SMA therapy

September 15, 2026 | msn.com

Scholar Rock (NASDAQ:SRRK) Shares Down 7.1% - Here's What Happened

September 15, 2026 | marketbeat.com

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

September 15, 2026 | benzinga.com

SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets

September 14, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MAZE, SRRK, ORKA, and MIRM Company Descriptions

Maze Therapeutics NASDAQ:MAZE

$25.98 -0.45 (-1.68%)

As of 02:11 PM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$82.17 +2.92 (+3.68%)

As of 02:11 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Oruka Therapeutics NASDAQ:ORKA

$79.80 -0.39 (-0.48%)

As of 02:11 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Scholar Rock NASDAQ:SRRK

$42.80 +0.35 (+0.82%)

As of 02:10 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MAZE, SRRK, ORKA, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MAZE, SRRK, ORKA, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MAZE, SRRK, ORKA, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MAZE, SRRK, ORKA, and MIRM Company Descriptions

Maze Therapeutics NASDAQ:MAZE

Mirum Pharmaceuticals NASDAQ:MIRM

Oruka Therapeutics NASDAQ:ORKA

Scholar Rock NASDAQ:SRRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MAZE, SRRK, ORKA, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MAZE, SRRK, ORKA, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MAZE, SRRK, ORKA, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MAZE, SRRK, ORKA, and MIRM Company Descriptions

Maze Therapeutics NASDAQ:MAZE

Mirum Pharmaceuticals NASDAQ:MIRM

Oruka Therapeutics NASDAQ:ORKA

Scholar Rock NASDAQ:SRRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools